JINXIN FERTILITY GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.6 HKD | +5.69% |
|
+14.54% | -22.39% |
| Sales 2024 * | 3.21B 443M 3.47B 606M | Sales 2025 * | 3.73B 515M 4.03B 704M | Capitalization | 6.64B 916M 7.17B 1.25B |
|---|---|---|---|---|---|
| Net income 2024 * | 441M 60.86M 476M 83.2M | Net income 2025 * | 521M 71.9M 563M 98.3M | EV / Sales 2024 * | 2.43 x |
| Net Debt 2024 * | 1.16B 159M 1.25B 218M | Net Debt 2025 * | 548M 75.58M 592M 103M | EV / Sales 2025 * | 1.93 x |
| P/E ratio 2024 * |
14.8
x | P/E ratio 2025 * |
12.2
x | Employees | 3,273 |
| Yield 2024 * |
3.77% | Yield 2025 * |
3.3% | Free-Float | 76.82% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +5.69% | ||
| 1 week | +14.54% | ||
| Current month | +7.00% | ||
| 1 month | +10.64% | ||
| 3 months | +11.11% | ||
| 6 months | -30.48% | ||
| Current year | -22.39% |
1 week
2.27
2.61
1 month
2.242.61
Current year
2.053.40
1 year
2.055.23
3 years
2.0523.50
5 years
2.0524.55
10 years
2.0524.55
| Managers | Title | Age | Since |
|---|---|---|---|
Yang Dong
CEO | Chief Executive Officer | 37 | 18-05-02 |
Rong Lyu
CEO | Chief Executive Officer | 43 | 21-12-02 |
Yong Zhong
CHM | Chairman | 52 | 18-09-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Min Fang
BRD | Director/Board Member | 45 | 18-12-24 |
John Wilcox
BRD | Director/Board Member | 61 | 18-12-24 |
Xiao Bo Wang
BRD | Director/Board Member | 49 | 19-06-02 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.17% | 3 M€ | -0.84% | - | |
| 0.14% | 2 M€ | -14.14% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 2.6 | +5.69% | 26,827,100 |
| 24-04-25 | 2.46 | -0.81% | 14,101,000 |
| 24-04-24 | 2.48 | +3.33% | 11,426,000 |
| 24-04-23 | 2.4 | +3.45% | 9,635,110 |
| 24-04-22 | 2.32 | +2.20% | 4,809,500 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am
More quotes
Jinxin Fertility Group Limited is a China-based company principally engaged in the provision of assisted reproductive services (ARS). The Company operates its business through three segments. The ARS segment primarily provides its patients with two treatment solutions: artificial insemination (AI) and in vitro fertilization (IVF) technology. The Management Services segment provides management services to Jinjiang IVF Center and Jinxin Fertility Center. The Ancillary Medical Services segment mainly provides medical services in the areas of gynecology, urology and internal medicine through Shenzhen Zhongshan Hospital. The Company mainly operates its business in China and the Unites.
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
2.407
CNY
Average target price
4.184
CNY
Spread / Average Target
+73.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.39% | 916M | |
| -14.92% | 84.68B | |
| +13.30% | 81.12B | |
| +10.92% | 29.4B | |
| -12.71% | 16.73B | |
| -3.06% | 16.36B | |
| -2.63% | 14.92B | |
| -31.75% | 11.77B | |
| -1.42% | 11.72B | |
| +27.44% | 11.71B |
- Stock Market
- Equities
- 1951 Stock
